Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Biotechnology

Healthcare
$37.75 -0.55%

-$0.29 today

Market cap
$3.71B
Beta
0.63
P/E (TTM)
-12.1
EPS (TTM)
-$4.39
52W Low $30.00High $63.95

Volume 1.30M

Average 1.16M

XENE Inventory

Raw materials, work in progress, and finished goods held for sale.

Xenon Pharmaceuticals Inc.NASDAQ: XENE

Inventory · Q3 FY2026 · quarter ended Sep 2026

Inventory remains negative

Q3 FY2026 inventory was $0, compared with $0 a year earlier.

Context

  • Inventory amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Inventory increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoSep 2025
$0— since
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Inventory vs competitors

How XENE compares with its peers on the latest reported figures

  • XENE's Sep 2026 inventory of $0 is the 7th highest of the 11 companies compared; the peer median is $21.01M.
  • Inventory amounts to 0.0% of total assets for XENE, versus a peer median of 0.8%.
XENE Competitors Peer median
Inventory for XENE and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JAZZJazz Pharmaceuticals plcSep 2026$454M -6.0%-16.4%3.8%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$83.92M +90.6%-3.5%5.9%
NBIXNeurocrine Biosciences, Inc.Sep 2026$66.1M -4.6%+25.3%1.2%
ACADACADIA Pharmaceuticals Inc.Sep 2026$40.36M +38.7%+73.5%2.2%
AXSMAxsome Therapeutics, Inc.Jun 2026$37.88M +105.4%+86.3%5.0%
DNLIDenali Therapeutics Inc.Jun 2026$4.14M ——0.4%
XENEXenon Pharmaceuticals Inc.Sep 2026$0 ——0.0%
PRAXPraxis Precision Medicines, Inc.Sep 2026$0 ——0.0%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
AVXLAnavex Life Sciences Corp.Dec 2025$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding XENE) $21.01M+38.7%+25.3%0.8%

Competitors are the stored peer set for XENE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents175.69M57.24M148.64M142.71M199.16M
Short-term Investments376.09M534.85M489.44M484.19M349.72M
Net Receivables2.77M986K874K1.47M1.37M
Inventory00000
Other Current Assets07.23M6.01M6.89M10.39M
Total Current Assets559.02M600.3M644.96M635.26M560.65M
Property, Plant & Equipment (Net)12.52M16.91M18.85M18.22M15.35M
Goodwill00000
Intangible Assets00000
Long-term Investments0128.68M292.79M127.5M37.15M
Tax Assets465K509K802K9.67M361.37M
Other Non-current Assets07.75M7.4M7.5M7.15M
Total Non-current Assets12.99M153.85M319.84M162.88M421.02M
Total Assets572.01M754.15M964.8M798.14M981.67M
Account Payables3.82M8.49M8.6M5.07M3.89M
Short-term Debt00001.53M
Tax Payables0005.69M0
Deferred Revenue00000
Other Current Liabilities5.94M5.82M347K9.93M21.6M
Total Current Liabilities14.32M22.7M27.27M35.59M41.79M
Long-term Debt00000
Deferred Tax Liabilities0000348.51M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00003.2M
Total Non-current Liabilities7.65M9.95M9.6M7.65M358.12M
Total Liabilities21.97M32.65M36.88M43.24M399.91M
Common Stock783.17M1.07B1.44B1.46B1.6B
Retained Earnings(357.37M)(482.75M)(665.14M)(899.47M)(1.25B)
Accumulated OCI(990K)(3M)(77K)(1.61M)335K
Other Stockholders Equity00000
Minority Interest00000
Total Equity550.03M721.5M927.92M754.9M581.76M
Total Debt8.26M10.44M10.9M9.02M7.94M
Net Debt(167.43M)(46.81M)(137.74M)(133.7M)(191.22M)

Xenon Pharmaceuticals Inc.

NASDAQ:XENE

Intrinsic Alpha fair value

Locked

Current Price

$37.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.